α-トコフェリルニコチネートのコレステロール代謝におよぼす影響にかんする臨床的ならびに実験的研究

概要

論文の詳細を見る
The oral administration of dl-α-tocopherylnicotinate (900mg, daily) to 21 hypercholesterolemic patients for 7-40 days was resulted in 14% decrease (p<0.001) in the serum total cholesterol levels with improvement of the subjective symptoms. Feeding of dl-α-tocopherylnicotinate or dl-α-tocopheryl acetate (as 0.24% dl-α-tocopherol) to mice for 21 days caused a decreased incorporation of acetate-1^<14>C into hepatic cholesterol. When dl-α-tocopherylacetate was injected to mice at a dose of 200mg/kg every five days for 60 days, the drug caused a decreased incorporation of acetate-1^<14>C into hepatic cholesterol, but had no effect when mevalonate-2^<14>C was used. When mice were fed a basal diet with 0.24% dl-α-tocopherylacetate for 21 days and cholesterol-4^<14>C was injected, the drug caused an increase of the fecal excretion of ^<14>C, decreases of hepatic cholesterol-^<14>C and the ratio of liver to blood free cholesterol specific activity derived from cholesterol-^<14>C. The results suggest that α-tocopherylnicotinate may produce serum cholesterol-lowering effect by inhibiting the biosynthesis of cholesterol and increasing the fecal excretion of cholesterol.
日本ビタミン学会の論文
1966-07-25